Pasithea Therapeutics

Biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders.

[Pasithea Therapeutics @PasitheaTx]

Looking forward to meeting Pasithea shareholders and investors in New York next week.

#KTTA #NASDAQ #Biotech

https://t.co/3yD4XdEW2d

[Pasithea Therapeutics @PasitheaTx]

Our findings will provide insight into #PAS004 preclinical efficacy, supporting further development of this #NF treatment candidate. #NFConference attendees, please join us, June 25th to learn more. https://t.co/rBlEe4AdJp

[Pasithea Therapeutics @PasitheaTx]

Exciting news for #NF1 patients as Koselugo gains approval in China! MEK inhibitors show promise in treating inoperable tumors from the rare disorder. We're developing a next-gen MEKi treatment to improve efficacy and overcome current limitations.
#EndNF1
https://t.co/as281FLBeS

[Pasithea Therapeutics @PasitheaTx]

This NF Awareness Month, we draw inspiration from the stories of those living with Neurofibromatosis. Each patient's experience is unique, but we are committed to finding a cure to #endnf. Let's raise awareness and support research to find a cure for this debilitating disease.

[Pasithea Therapeutics @PasitheaTx]

Looking forward to meeting Pasithea shareholders and investor community professionals in NY this week.
$KTTA #MEKinhibitor #RASopathies #biotech

https://t.co/IjHJfbYg5G

[Pasithea Therapeutics @PasitheaTx]

Congratulations to Biogen for the first approved drug (tofersen) to target a specific gene mutation in ALS.

https://t.co/fo5t0bUcjv

[Pasithea Therapeutics @PasitheaTx]

Pasithea chairman, Prof Lawrence Steinman discusses the potential for his work identifying the connection between Epstein-Barr virus and #MS.

#MS #EBV #mononucleosis #PAS002 

https://t.co/EJHQZTQeEf

[Pasithea Therapeutics @PasitheaTx]

For groundbreaking research linking #Epstein-Barr virus to #multiplesclerosis, 2022 @ScienceMagazine Breakthrough of the Year runner up
#immunology $KTTA

https://t.co/8GhEoSzCnv

[Pasithea Therapeutics @PasitheaTx]

Prof. Larry Steinman, Pasithea's Chairman, to deliver Dr. Kenneth P. Johnson lecture at ACTRIMS meeting, focusing on how Epstein-Barr virus triggers MS. The ACTRIMS meeting showcases novel discoveries in MS research. #MS #MSvaccine $KTTA #PAS002 @ACTRIMS

https://t.co/VuzM0QKMLN

[Pasithea Therapeutics @PasitheaTx]

Congrats to #PasitheaTx Chairman for his award from @WorldBrainMap and @BrainMappingFdn for his contributions to brain mapping and therapeutics, the basis of our #multiplesclerosis drug discovery program. Well-deserved recognition! #CNS #GlialCAM $KTTA

https://t.co/4lOIDrsjmz

[Pasithea Therapeutics @PasitheaTx]

A final step before submission of our IND application to initiate human, clinical trials, planned for 2H23.
#EndNF #MEK  #neurofibromatosis $KTTA #biotech

https://t.co/pD8L9mhZH7

[Pasithea Therapeutics @PasitheaTx]

The Alpha-5 acquisition is transformative for Pasithea, by adding a new drug with a novel mechanism of action to our pipeline, while preserving our strong cash position.” stated Dr. Tiago Reis Marques, CEO of Pasithea.

Visit https://t.co/FRahgCsFvv to learn more.

#alpha5

[Pasithea Therapeutics @PasitheaTx]

Pasithea has partnered with Glimpse to bring VR and AR environments to support the treatment of patients with psychiatric disorders in a safe and effective manner.

Find out more here: https://t.co/1Ys4MoiERq

#psychiatric #neurologicaldisorders #VR #mentalhealth #pasithea

[Pasithea Therapeutics @PasitheaTx]

According to the @WHO, around 280 million people in the world have depression.

Pasithea provides treatments in the US and in the UK for treatment-resistant depression, PTSD, bipolar disorder and acute anxiety.

#ketamine #pasithea #depression #bipolar #anxiety

[Pasithea Therapeutics @PasitheaTx]

Pasithea is led by a world class management team of renowned experts in immunology and neuroscience.

The company vision is to transform the treatment of people who suffer from psychiatric and neurological disorders.

Visit https://t.co/FRahgCsFvv to learn more.

#pasithea

[Pasithea Therapeutics @PasitheaTx]

We are pleased to announce that our second clinic in the United Kingdom is now open. We are on a mission to open clinics across the UK to increase support for patients with treatment-resistant mental health disorders.

Visit https://t.co/o9aMhZjcMD to learn more.

#pasithea

[Pasithea Therapeutics @PasitheaTx]

“@Dr_Weinberger’s expertise and insight will be critical to Pasithea as we advance our mission of developing drugs that target the pathophysiology underlying psychiatric and neurological disorders.” Dr Tiago Reis Marques, CEO of Pasithea Therapeutics.

https://t.co/hrTTMeYHAw

[Pasithea Therapeutics @PasitheaTx]

Our goal is to develop a tolerizing vaccine for multiple sclerosis (‘MS’), a potentially disabling autoimmune disease in which the immune system attacks myelin, the protective sheath that surrounds nerves in the brain and spinal cord.

Visit https://t.co/7Kv1lhxEZq to learn more.

[Pasithea Therapeutics @PasitheaTx]

We are excited to announce our latest clinic opening in Los Angeles, California which will provide intravenous ketamine and other therapies to patients suffering from treatment-resistant mental health issues.

Visit https://t.co/1nnNkXFB9U to learn more about the treatment.

[Pasithea Therapeutics @PasitheaTx]

We are launching our new in-home Ketamine treatment for people who have been suffering from treatment-resistant mental health disorders in New York, Los Angeles, San Diego and San Francisco.

Visit https://t.co/1nnNkXFB9U to learn more about the treatment.
#mentalhealth